

FECAL MICROBIOTA TRANSPLANTATION: A COMPREHENSIVE REVIEW**Silky Rai*, Subuhi Anwar**, Mehnaz Khan*****Department of Oncopathology*, Department of Pathology***

Tata Memorial Centre, Mahahmana Pandit Madan Mohan Malviya Cancer Centre and Homi Bhabha Cancer Hospital, Varanasi, U.P., India-221005*.

Era's Lucknow Medical College and Hospital, Era University, Sarfarazganj, Lucknow, U.P., India-226003**.

Received on : xx-xx-xxxx
Accepted on : xx-xx-xxxx

ABSTRACT

The goal of fecal microbiota transplantation (FMT), a therapeutic technique, is to restore the balance of gut microbiota by giving a recipient fecal material from a healthy donor. Modern clinical uses of FMT, which have their roots in ancient Chinese medicine, were well-known in the 1950s, especially for the treatment of severe *Clostridium difficile* infections (CDI). The importance of microbiota in human health is highlighted by the human microbiome, which is made up of billions of microorganisms that are essential for immunity, metabolism, and disease resistance. An imbalance in the makeup of the microbiota known as dysbiosis is linked to a number of illnesses, underscoring the potential therapeutic benefits of FMT. This review covers all the bases regarding FMT its history, current clinical uses in gastrointestinal disorders such as inflammatory bowel disease (IBD) and CDI, technological developments, regulatory issues, emerging clinical uses in neurological and metabolic disorders, and future directions for research. The review highlights FMT's effectiveness, safety concerns, and implications for healthcare strategy by synthesizing the body of existing literature. Research is still being done to improve procedures, investigate customized microbiota-based treatments, and expand the uses of FMT outside of gastrointestinal disorders. In order to advance FMT as a transformational therapy in precision medicine, cross-disciplinary collaboration is essential.

KEYWORDS: Therapeutic, Dysbiosis, Fecal microbiota, Disorders.

INTRODUCTION

The goal of fecal microbiota transplantation (FMT), a therapeutic treatment, is to restore a disturbed gut microbiota and reduce symptoms of disease by transferring fecal material from a healthy donor to a recipient. Modern therapeutic uses of FMT gained popularity in the 1950s with successful treatments against severe instances of *Clostridium difficile* infection (CDI), a history that dates back to ancient Chinese medicine (1). Since then, FMT has developed into a potentially effective therapy option for a variety of gastrointestinal problems, and its application in treating ailments other than those of the gut is being investigated more and more.

The billions of bacteria that live in different parts of the human body, known as the microbiome, are essential to both promoting and preserving health. Specifically, the gut microbiota supports immune function regulation, host metabolism, and pathogen defense (Lloyd-Price et al., 2016 2). An imbalance in the composition of the

microbiota known as dysbiosis has been linked to a number of illnesses, highlighting the vital role that microbial communities play in human physiology.

An extensive analysis of fecal microbiota transplantation is intended, including its historical evolution, present therapeutic uses, technological developments, regulatory issues, new clinical applications, and potential future research avenues. The goal of this review is to demonstrate the potential of FMT in clinical practice and its implications for future research and healthcare initiatives by synthesizing the available literature and analyzing major findings.

Fecal Microbiota Transplantation (FMT) Mechanisms

The Gut Microbiota's Function in Maintaining Health: A vital component of human health is the gut microbiota, which is made up of many bacterial species, fungi, viruses, and archaea. According to Lloyd-Price et al. (2016), it supports host metabolism, synthesizes vital vitamins, teaches the immune

Address for correspondence**Dr. Silky Rai**

Department of Oncopathology
Mahahmana Pandit Madan Mohan Malviya
Cancer Centre, Varanasi-221005.

Email: drsilkyrai@gmail.com

Contact no: +91-

In gastroenterology and beyond, functional movement therapy (FMT) is a fast developing discipline that has shown promise in treating irritable bowel syndrome, inflammatory bowel diseases, and neurological and metabolic problems. It has been proven effective in treating Crohn's disease (CDI). To optimize patient selection criteria, clarify mechanisms of action for a range of clinical diseases, and refine protocols, ongoing research is crucial. Safety Considerations in FMT and Donor Screening

Choosing Appropriate Donors for FMT Is Essential: To guarantee the procedure's safety and effectiveness, it is essential to choose appropriate donors for FMT. Excellent general health, no gastrointestinal illnesses or infections, and a well-defined and stable gut microbiota composition are desirable qualities in donors (1). A few elements taken into account while choosing a donor are:

1. **Health Screening:** In order to rule out infectious diseases and other medical disorders that could endanger recipients, donors go through extensive health screenings that include a medical history, physical examination, and laboratory testing (such as blood and stool tests).
2. **Microbiota Composition:** Given that microbial diversity and composition can affect the results of FMT, donors should have a stable and diverse gut microbiota (3).
3. **Behavioural Screening:** To reduce potential exposure to pathogens or factors that could impact the makeup of the gut microbiota, lifestyle factors like food, medication usage, and travel history are also reviewed.

Screening Procedures to Reduce the Risk of Spreading Infections: Comprehensive screening measures are used during FMT to reduce the possibility of infection transmission:

1. **Testing for Infectious Diseases:** Using stool culture methods, molecular diagnostics, and serological testing, donors are examined for a variety of infectious agents, including as bacteria, viruses, parasites, and fungus (13).
2. **Stool Testing:** To ensure that stool samples are suitable for transplantation, a thorough study is performed on them to identify infections and evaluate the microbial composition (4).
3. **Exclusion Criteria:** Donors who have recently taken antibiotics, a history of gastrointestinal issues, have recently travelled to an area where an infection is endemic, or engages in high-risk activities for infectious diseases are not eligible.

Possible Long-Term Hazards and Issues Related to FMT

1. **FMT has long-term problems and other hazards despite its effectiveness:** Transmission of Infections: Tight screening lowers the danger, but there is still a chance that donors and recipients will become infected or colonized with opportunistic pathogens .
2. **Gastrointestinal Symptoms:** Following FMT, some recipients may have brief gastrointestinal symptoms, such as bloating, diarrhea, or discomfort in the abdomen. These symptoms usually go away on their own.
3. **Immunological Risks:** Research is still being done on the long-term consequences on host immunological responses and the interactions that occur between the recipient immune system and the transplanted microbiota (5).
4. **Unknown Risks:** More research is need to determine the long-term effects of modifying gut microbiota with FMT on immunological response, metabolic health, and susceptibility to chronic diseases (4)

FMT Regulation and Standardization

1. **Provide the FMT Procedure Guidelines:** While specific regulations may vary, FMT techniques are generally governed by a range of national and international standards. Important subjects that are frequently covered include
2. **Donor screening:** Strict guidelines are applied to select suitable donors to lower the risk of infection transmission. These guidelines include health evaluations, microbiota profiling, and the exclusion of high-risk behaviours (1).
3. **Preparation of Fecal Material:** To maintain microbial viability and composition, donor stool is prepared using standardized techniques such as homogenization, dilution, and filtering (4).
4. **Administration Techniques:** To optimize treatment effectiveness, recommendations for the route of administration (e.g., enema, capsules, and colonoscopy) are based on the features of the patient, the severity of the condition, and the clinical setting (1).

Particular Difficulties in Standardizing FMT Procedures

1. **Microbial Composition and Diversity:** It is difficult to establish a universal "standard" microbiota preparation that ensures consistent treatment outcomes due to donor stool

REFERENCES

1. Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. *Gut*. 2017;66(4):569-580.
2. Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. *Genome Med*. 2016; 8(1): 51.
3. Allegretti JR, Fischer M, Sagi SV, et al. Fecal microbiota transplantation for Clostridioides difficile infection in a real-world setting: A single-center experience of 100 consecutive patients. *Dig Dis Sci*. 2021; 66(1): 142-149.
4. Ianiro G, Murri R, Sciumè GD, et al. Incidence of bloodstream infections, length of hospital stay, and survival in patients with recurrent Clostridioides difficile infection treated with fecal microbiota transplantation or antibiotics: A prospective cohort study. *Ann Intern Med*. 2019; 171(10): 695-702.
5. Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: A randomized trial. *Ann Intern Med*. 2016; 165(9): 609-616.
6. Kootte RS, Levin E, Salojärvi J, et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. *Cell Metab*. 2017; 26(4): 611-619.e6.
7. Pamer EG. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. *Science*. 2016;352(6285):535-538.
8. Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: A randomised placebo-controlled trial. *Lancet*. 2017; 389(10075): 1218-1228. doi:10.1016/S0140-6736(17)30182-4
9. Staley C, Kaiser T, Beura LK, et al. Stable engraftment of human microbiota into mice with a single oral gavage following antibiotic conditioning. *Microbiome*. 2017;5(1):87. doi:10.1186/s40168-017-0310-5
10. Johnsen PH, Hilpusch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. *Lancet Gastroenterol Hepatol*. 2018;3(1):17-24. doi:10.1016/S2468-1253(17)30338-2
11. Kang DW, Adams JB, Gregory AC, et al. Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. *Microbiome*. 2017;5(1):10. doi:10.1186/s40168-016-0225-7
12. Friedman-Moraco RJ, Mehta AK, Lyon GM, Kraft CS. Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients. *Am J Transplant*. 2020;20(9):2595-2601. doi:10.1111/ajt.15969
13. Gupta S, Allen-Vercoe E, Petrof EO. Fecal microbiota transplantation: in perspective. *Therap Adv Gastroenterol*. 2021; 14: 1756284821992947. doi:10.1177/1756284821992947
14. US Food and Drug Administration (FDA). Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. Updated July 2020. Accessed June 24, 2024. FDA website



Orcid ID:

xxxxxxxxxxxxxx - <https://orcid.org/>

How to cite this article:

Sharma S., Agrawal V., Ali S.S., Gupta P. Accessory Breast Tumor In Male – Rare Case. Era J. Med. Res. 2024; 11(1): X-X.

Licencing Information

Attribution-ShareAlike 2.0 Generic (CC BY-SA 2.0) Derived from the licencing format of creative commons & creative commons may be contacted at <https://creativecommons.org/> for further details.